Perfuse Therapeutics
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
611 Gateway Blvd Ste 910, South San Fran...Website
www.perfusetherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Perfuse Therapeutics
Perfuse Therapeutics is focused on developing innovative therapies aimed at reducing blindness, particularly through improving blood flow to the retina. Their primary product is a first-in-class endothelin antagonist designed to enhance ocular blood flow, targeting conditions such as glaucoma and diabetic retinopathy. The company is backed by a team with extensive expertise in ocular drug discovery and a strong network of venture capital firms specializing in ophthalmology. Their mission addresses the significant global health issue of blindness caused by these prevalent ocular diseases.Explore more
Perfuse Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Perfuse Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Perfuse Therapeutics has new funding data
Check out if Perfuse Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Perfuse Therapeutics
Product Launch: Get notified when Perfuse Therapeutics launches new products
Check if Perfuse Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Perfuse Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Perfuse Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Perfuse Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Perfuse Therapeutics
Compare insights from companies similar to Perfuse Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Perfuse Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Perfuse Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Perfuse Therapeutics.
Perfuse Therapeutics Tech Stack
A closer look at the technologies used by Perfuse Therapeutics
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Person-Based
Person-Based
Person-Based
Perfuse Therapeutics News & Media
Bayer buys Perfuse in $2.4B deal for ph. 2 eye disease prospect - Fierce Biotech
Bayer has struck a deal to buy Perfu | The buyout, which includes up to $2.15 billion in milestones, will give Bayer control of an eye disease implant that Perfuse linked to improved outcomes in a pair of phase 2 trials last year.Perfuse Therapeutics Announces Positive Results from Phase 2 Clinical Trials in Glaucoma and Diabetic Retinopathy Patients
PER-001 intravitreal implant shows potential to be the first disease-modifying treatment for both glaucoma and diabetic retinopathy Progressive vision loss reversed in glaucoma patients as optic nerve blood flow and structure improved Diabetic retinopathy patients experience improvements...Perfuse Therapeutics Announces Positive Results from the Completed Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma
– A single intravitreal administration of PER-001 improved both visual function and anatomic structure compared to control at 24 weeks – – These data support the potential of PER-001 as the first disease-modifying treatment for glaucoma – –PER-001 improved ocular blood flow, validating...Perfuse Therapeutics Announces Oral Presentation on PER-001 Intravitreal Implant for Glaucoma at the Association for Research in Vision and Ophthalmology (ARVO) Meeting
– Oral presentation to highlight 6-month data from all cohorts of the completed Phase 1/2a clinical trial – SAN FRANCISCO, April 21, 2025 /PRNewswire/ -- Perfuse Therapeutics, Inc. ("Perfuse Therapeutics"), a biopharmaceutical company pioneering transformational therapies to treat...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Perfuse Therapeutics
Sign Up For FreeTo access detailed company insights
Perfuse Therapeutics is focused on developing innovative therapies aimed at reducing blindness, particularly through improving blood flow to the retina. Their primary product is a first-in-class endothelin antagonist designed to enhance ocular blood flow, targeting conditions such as glaucoma and diabetic retinopathy. The company is backed by a tea... Read More
